Summary:
Risk-adapted treatment of multiple myeloma (MM) includes autologous (auto-) and allogeneic (allo-) hematopoietic stem cell transplantation (HSCT). Case reports on extramedullary (EM) compared to bone marrow (BM) relapse after HSCT suggest a dismal prognosis. We compared the outcome of 78 MM patients relapsing after auto- (group A: n=53) or allo- (group B: n=25) HSCT, stratified into BM (64 patients) vs EM (14 patients) relapse. The relapse-specific groups were also compared with respect to risk factors, including age, β2-microglobulin, pretreatment, cytogenetics and stage. EM relapse sites were lungs (5), soft tissue (4), pericardium (2), bone (1), skin (1) and CNS (1). As of May 2004, the overall (OS) and progression-free (PFS) survival after HSCT in patients relapsing from EM sites was not significantly different from BM relapse patients, both after auto- and allo-HSCT. Although MM patients relapsing from EM sites after allo-HSCT used to be regarded as having few therapeutic options, we observed encouraging responses to donor lymphocyte infusions (DLI). Treatment responses to DLIs were observed in 5/9 (56%) BM relapse patients, and in 3/4 (75%) EM relapse patients. These observations suggest that EM relapse after HSCT is common and needs an individualized diagnostic and therapeutic approach in MM during clinical follow-up after HSCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.
Attal M, Harousseau JL, Facon T et al. Single vs double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.
Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447–1453.
Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–795.
Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2792.
Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1317.
Rosler W, Strobel G, Sendler A et al. Relapse of light-chain myeloma after allogeneic bone marrow transplantation: no recurrence of myeloma protein. Bone Marrow Transplant 1996; 17: 71 (abstr. 329).
Zomas A, Stefanoudaki K, Fisfis M et al. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmocytomas. Bone Marrow Transplant 1998; 21: 1163–1165.
Umeno Y, Kogawa K, Matsuishi E et al. A case of multiple myeloma which developed into multiple extramedullary involvement in the terminal stage. Fukuoka Igaku Zasshi 2000; 91: 55–61.
Richardson PG, Barlogie B, Berenson J et al. A phase II study of bortezomib in relapsed and refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
Metha J . The graft-versus-myeloma effect. In: Barrett AJ, Jiang YZ (eds). The Graft-Versus-Leukemia Effect in Allogeneic Stem Cell Transplantation. Marcel-Dekker: New York, 1998.
Aleya EP, Schlossman RL, Canning C et al. CD8-depleted donor lymphocyte infusions mediate graft-versus-multiple-myeloma (MM) effect. Blood 1996; 87: 258a (abstr. 1021).
van der Griend R, Verdonck LF, Veenhuizen P et al. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 195–197.
Gore ME, Selby PJ, Viner C et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2: 879–883.
Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose chemotherapy and haematopoietic stem cell transplantation. Meyloma Subcommittee of the EBMT. European Group of Blood and Marrow Transplantation. Br J Haematol 1998; 102: 1115–1123.
Goldschmidt H, Hegenbart U, Wallmeier M et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol 1997; 8: 243–246.
Neidhart JA, Kohler W, Stidley C et al. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. J Clin Oncol 1990; 8: 1728–1738.
Johnson RJ, Owen RG, Smith GM et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 1996; 17: 723–727.
Finke J, Brugger W, Bertz H et al. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. Bone Marrow Transplant 1996; 18: 1081–1086.
Palumbo A, Bringhen S, Bertola A et al. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2). Leukemia 2004; 18: 133–138.
Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588–595.
Wäsch R, Reisser S, Hahn J et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 2000; 26: 243–250.
Bertz H, Potthoff K, Mertelsmann R et al. Busulfan/cyclophospamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997; 19: 1169–1175.
Finke J, Bertz H, Schmoor C et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000; 111: 303–313.
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Mantel N . Evaluation of survival data and two new rank order statistics arising in ist consideration. Cancer Chemother Rep 1966; 50: 163–170.
Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680–1685.
Alexanian R, Dimopoulos MA, Delasalle K et al. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–890.
Bjorkstrand B, Ljunman P, Bird JM et al. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 1995; 13: 140–146.
Singhal S, Powles R, Sirohi B et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673–679.
Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3013–3037.
Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179–1184.
Bertz H, Burger JA, Kunzmann R et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic BMT: evidence of a graft-versus-myeloma effect. Leukemia 1997; 11: 281–283.
Harousseau JL . Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. Haematology 1999; 84: 548–553.
Attal M, Harrousseau JL . Randomized trial experience of the Intergroupe Francophone du Myelome. Sem Hematol 2001; 38: 226–230.
Lemoli RM, Martinelli G, Zamagni E et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood 2000; 95: 2234–2239.
Schiller G, Vescio R, Freytes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390–397.
Bellaïche L, Laredo HD, Loité F et al. Magnetic resonance appearance of monoclonal gammopathies of unknown significance and multiple myeloma. Spine 1997; 22: 2551–2557.
Carlson K, Astrom G, Nyman R et al. MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment. Acta Radiol 1995; 36: 9–14.
Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.
Singhal S, Mehta J . Novel therapies in myeloma. Int J Hematol 2003; 77: 226–231.
Acknowledgements
We are grateful to Dr Cathleen McSharry for carefully proof-reading this manuscript. We appreciate the support of the transplant coordinator Mrs Lenartz, the data coordinator Mrs Matt and the entire transplantation staff of the Department of Hematology and Oncology of the Freiburg University Medical Center for their excellent support and patient care.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zeiser, R., Deschler, B., Bertz, H. et al. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 34, 1057–1065 (2004). https://doi.org/10.1038/sj.bmt.1704713
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704713
Keywords
This article is cited by
-
Extramedullary relapse of Immunoglobulin A-kappa myeloma manifesting as plasmacytoma of the pleura without bone marrow involvement and following autologous bone marrow transplant: a case report
Journal of Medical Case Reports (2023)
-
Extramedullary multiple myeloma
Leukemia (2020)
-
Therapie des rezidivierten und refraktären multiplen Myeloms
Der Onkologe (2018)
-
Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
Blood Cancer Journal (2015)
-
Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
Bone Marrow Transplantation (2014)